Seiichi Murakami
Direktor/Vorstandsmitglied bei Medicago, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Hiroaki Ueno | M | 65 | 17 Jahre | |
Eizou Tabaru | M | 65 | 10 Jahre | |
Takashi Nagao | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
Matsuo Kikuchi | M | 64 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 40 Jahre |
Yoshihiro Kobayashi | M | 63 | 41 Jahre | |
Yoshihisa Sasou | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 11 Jahre |
John Wallace | M | 67 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
Marc-André D'Aoust | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 25 Jahre |
To fart Luongo | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 11 Jahre |
Koji Kudo | M | 66 | 8 Jahre | |
Christina Cameron | F | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
Naoya Sato | M | - | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Kuniaki Kaga | M | 72 | - | |
Minoru Muramatsu | M | - | - | |
Yoshiaki Ishizaki | M | 69 | 12 Jahre | |
Toshifumi Tada | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 6 Jahre |
Kenkichi Kosakai | M | 70 | 8 Jahre | |
Bruce Clark | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 7 Jahre |
Kuniyoshi Wada | M | - | - | |
Masayuki Mitsuka | M | 69 | - | |
Takashi Tanaka | M | 67 | 34 Jahre | |
Takeshi Matsumoto | M | 67 | - | |
Shigeki Iwane | M | 71 | - | |
Kazutoshi Murao | M | 71 | - | |
Takashi Kobayashi | M | 68 | - | |
Koji Nakamura | M | 73 | - | |
Carolyn Finkle | F | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 2 Jahre |
Shigehiko Hattori | M | 82 | 8 Jahre | |
Tsutomu Kamijo | M | 70 | - | |
Shigetaka Sato | M | 83 | 2 Jahre | |
Pierre des Marais | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 4 Jahre |
Pierre Labbé | M | 58 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 9 Jahre |
Kazufumi Watanabe | M | - | 4 Jahre | |
Seiichi Kiso | M | - | - | |
Koichi Fujisawa | M | 72 | 5 Jahre | |
Shotaro Yoshimura | M | 75 | 7 Jahre | |
Todd Lewis Talarico | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
Yatika Kohli | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
Jung Kai Shao | M | - | - | |
Seishiro Yoshioka | M | 79 | - | |
Tsuyoshi Okuno | M | - | 17 Jahre | |
Junji Hamaoka | M | 73 | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Japan | 29 | 69,05% |
Kanada | 14 | 33,33% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Seiichi Murakami
- Persönliches Netzwerk